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miRNAYin Yang 1 (YY1) is amember of polycombprotein family involved in epigeneticmodiﬁcations and transcription-
al controls. We have shown that YY1 acts as positive regulator of tumor growth and angiogenesis by interfering
with theVEGFAnetwork. Yet, the link between polycomb chromatin complex and hypoxia regulation of VEGFA is
still poorly understood. Here, we establish that hypoxia impairs YY1 binding to VEGFA mRNA 3′UTR (p b 0.001)
in bone malignancy. Moreover, RNA immunoprecipitation reveals the formation of triplex nuclear complexes
among YY1, VEGFA DNA, mRNA, and unreached about 200 fold primiRNA 200b and 200c via Dicer protein. In
this complex, YY1 is necessary tomaintain the steady-state level of VEGFAexpressionwhile its silencing increases
VEGFA mRNA half-life at 4 h and impairs the maturation of miRNA 200b/c. Hypoxia promotes histone modiﬁca-
tion through ubiquitination both of YY1 andDicer proteins. Hypoxia-mediated down-regulation of YY1 andDicer
changes post-transcriptional VEGFA regulation by resulting in the accumulation of primiRNA200b/c in compari-
son to mature miRNAs (p b 0.001). Given the regulatory functions of VEGFA on cellular activities to promote
neoangiogenesis, we conclude that YY1 acts as novel critical interface between epigenetic code and miRNAs
machinery under chronic hypoxia in malignancy.
© 2015 Published by Elsevier B.V.1. Introduction
Tumor adaptive response to hypoxia involves a variety of epigenetic,
transcriptional and posttranscriptional events [1]. Several lines of evi-
dence establish that hypoxia is an important regulator of histone mod-
iﬁcations, miRNA biogenesis and function [1,2].
The evolutionary conserved Polycomb proteins (PcGs) modify chro-
matin structure promoting histonemethylation, or monoubiquitination
[3,4] and preserve epigenetic memory [5,6]. In addition, PcGs control
transcriptional programs, [7] acting as repressors in normal tissues
[7,8]. PcGs can form two complexes the repressive complex 1 (PRC1)
which includes proteins such as Yin Yang 1 (YY1), BMI1, HPH1–3, HPC
proteins, RING1A–1B [9] and PRC2/3/4 with core protein EZH2 [10,11].
YY1 is associated with both complexes [12] and it is the only PcG
protein with a sequence-speciﬁc DNA binding element (CCATnTT) and
RNA binding properties [13]. Although, YY1 is mainly described as aris).transcription factor [13], the association between YY1 and PRC1/2 pro-
vides a direct link between the chromatin-PcG complex and the DNA
of target genes [14].
YY1 has been shown to be involved in the development and/or
progression of several solid and hematological tumors by interacting
with cell cycle regulation. Indeed, YY1 overexpression is associated
with unchecked cellular proliferation, resistance to apoptotic stimuli,
tumorigenesis and metastatization [15–17]. Our previous ﬁndings
have identiﬁed that YY1 is overexpressed in bone malignancy favoring
tumor growth [18–20]. Silencing of YY1 can reduce vessel formation
and neoangiogenesis [20–22]. Since the vascular endothelial growth fac-
tor A (VEGFA) is a powerful effector of neoangiogenesis under hypoxic
condition [23] and it is the most frequently duplicated gene in malig-
nancy of the bone, [24–27], it would be interesting to deﬁne the regula-
tive cross talk between YY1/VEGFA.
MicroRNAs (miRNAs) are small RNA molecules with a regulatory
function and tissue speciﬁcity that modulate several target genes in-
volved in cellular processes such as proliferation, differentiation and apo-
ptosis. They predominantly target the 3′UTR mRNA and are frequently
deregulated in cancer. In this context, YY1 has shown to be the target of
several miRNAs in different tumor types thus acting as tumor activator
or suppressor [28,29].
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partecipates posttranscription regulation of VEGFA by providing a criti-
cal interface between chromatin remodelling and miRNA complexes.
2. Results
2.1. Role of polycomb YY1 on VEGFA expression during hypoxia
To understand whether YY1 could regulate speciﬁc VEGFA isoforms,
we analyzed VEGFA mRNA isoforms 121, 165, and 189 in osteoblasts
and osteosarcoma cell lines. In normal osteoblastic cells, VEGFA 165
mRNA was the predominant isoform, accounting for 78.8% of total
VEGFA transcripts whereas in osteosarcoma cells it varied between 3
and 20% of total mRNAs, as well as VEGFA 121 (Fig. 1A). Despite changes
in the expression of different isoforms, the amount of total VEGFA mRNA
was higher in normal cells vs. osteosarcomas (Fig. 1B). As expected, the
ratio between pro- and anti-angiogenic VEGFA isoforms was shifted to-
wards the pro-angiogenic in osteosarcoma cells while in normal cells the
two isoformswere balanced (Suppl. Fig. 1). The effect of YY1 and its undis-
tinguished homologous YY2 on VEGFAmRNA isoformswere evaluated by
using stable cell lines silenced for YY1/2, (Suppl. Fig. 2A, B). As indicated in
Fig. 1B, silencing of YY1/2, both in Saos andU2os cells, determined a signif-
icant accumulation of VEGFAmRNAs 121/165whichwasmore evident as
protein accumulation monitored by ELISA (Fig. 1C) and western blots vs.
controls Saos and U2os pBlock-it cells (Fig. 1D). No VEGFA protein accu-
mulation was observed in osteoblasts (Fig. 1C and D). Hypoxia, which
stimulates tumor cells to release VEGFA, increased very low VEGFA tran-
scripts in Saos pBlock-it cells (Fig. 1E). In contrast, hypoxia determined a
four- fold higher protein accumulation vs. normoxia in Saos pBlock-it
cells (Fig. 1F and G). These phenomena were less evident in shYY1/2
cells (Fig. 1F and G and Suppl. Fig. 2C). Interestingly, HIF-1α was
down-regulated in shYY1/2 cells in both hypoxic and normoxic condi-
tions (Fig. 1F).
2.2. YY1 inﬂuences the stability of VEGFA 121/165 mRNA
During normoxia, the silencing of YY1/2 increases VEGFA protein
more than its mRNA. We hypothesized that YY1 could affect its
stability. Indeed, osteoblasts (Ost) and cancer cells were treated with
actinomycin D to block transcription. VEGFA 121/165 mRNAs were
then measured at the indicated time points. The real time PCR data
conﬁrmed the general knowledge that VEGFA 121 and 165 mRNA
half-life were 20 min in normal cells (Fig. 2A) and 15 min in tumor
cells (Fig. 2B and C). In contrast, the half-life of these two VEGFA
isoforms was prolonged up to about 4 h in both U2os (Fig. 2D) and
Saos cells silenced for YY1/2 (Fig. 2E). Therefore, it is likely that the sta-
bilization of VEGFA transcripts accounts for the higher steady state level
of VEGFAmRNAand in accordancewith the accumulation of VEGFApro-
tein in response to YY1/2 silencing (Fig. 1C, D, F, and G). Yet, VEGFA
mRNA stability measurements which are known to be dependent on
phosphorylation of posttrascriptional regulator proteins [30–33] were
also performed in the presence of PD98059 and SB239063 inhibitors
MAPKinase pathway. Both inhibitors increase VEGFA 121/165 mRNAs
half life in normal and tumor cells (Fig. 2A–C). Interestingly, PD98059 and
SB239063 did not affect VEGFA mRNA stability in shYY1/2 cell lines
(Fig. 2D and E). These ﬁndings suggest that YY1 could interfere with the
same pathway. Finally, hypoxia increases stability of VEGFA 121 and 165
mRNAs in Saos pBlock-it cells (Fig. 2F) while did not in shYY1/2 cells
(data not shown). Thus, YY1 could play different roles in the posttranscrip-
tional regulation of VEGFA in normoxia vs. hypoxia conditions.
2.3. VEGFA chromatin status in normoxia and hypoxia
VEGFA is posttranscriptionally controlled by the miRNA machinery
and through the binding of stabilizing and destabilizing proteins to
the AU-rich element (ARE) domains located in the 3′UTR and 5′UTR ofits mRNA [30–33]. In order to investigate the mechanism underlying
the inﬂuence of polycomb YY1 on VEGFA mRNA stability, VEGFA
gene was scanned for YY1 consensus binding sites with MatInspector
Professional 8.0 software (http://www.genomatix.de). The analysis re-
vealed several YY1 binding sites in the 3′UTR region (Fig. 3A). To inves-
tigate for possible physical interactions with genomic DNA, we carried
out ChIP assays using anti-YY1 antibody and real time PCR on pulled-
down material in Saos cells. Among all predicted binding sites, the
amplicons of two of them, located approximately at positions
CHR6:43752323 + 43752800 and CHR6:43753242 + 43753823 of
the VEGFA 3′UTR (called region 1 and 2 respectively), were enriched
after YY1 immunoprecipitation (Fig. 3A). We performed such experi-
ments in normoxic and hypoxic conditions by investigating epigenetic
marks due to the involvement of YY1 in epigenetic modiﬁcations. In
normoxia, data reported as fold change over non-immunoprecipitated
DNA, revealed that histonemethylation (H3K27me3) was 7 fold higher
in region 1 than to region 2 (Fig. 3B and Suppl. Fig. 3A, B) and YY1 pro-
tein enriched (about 3 fold) region 1 compared to region 2 (Fig. 3B). No
enrichmentwas observedwith IgG antibodies showed as semiquantita-
tive gel analysis (Suppl. Fig. 3A, B). During hypoxia, YY1 protein
enriched region 2 and histone H2A was ubiquitinated compared to re-
gion 1, (Fig. 3C and Suppl. Fig. 3A, B). Silenced of YY1/2 did not inﬂuence
histone methylation of region 1 (Suppl. Fig. 3A, B) while affected H2A
ubiquitination at region 2 (Fig. 3A and Suppl. Fig. 3B) suggesting that
YY1 may be involved in epigenetic modiﬁcation during hypoxia.
2.4. Polycomb YY1 is recruited on VEGFA mRNA during normoxia and
hypoxia
Since polycombYY1protein can bind bothDNAandRNA, [34,35] and
because we observed a binding to the 3′UTR region of the VEGFA gene,
we hypothesized that YY1 may bind also VEGFA mRNA (Fig. 4A). To in-
vestigate interactions between YY1 and VEGFA mRNA, we performed
RNA immunoprecipitation (RNA ChIP) with anti-YY1, anti-HIF-1α and
anti-TTP antibodies following crosslinking of RNA to protein. We
analyzed these interactions both in normoxia and hypoxia. Real
time PCRs of YY1 pull-down material (performed with primer sets
on 5/7 exons junction see Table 1) showed signiﬁcant co-
immunoprecipitation of VEGFA mRNA in normoxia (Fig. 4B) also
showed as semiquantitative gel analysis (Suppl. Fig. 4A). Data, re-
ported as fold enrichment over non-immunoprecipitated samples,
indicated that interaction between VEGFA mRNA and YY1 was spe-
ciﬁc. This was evident from the absence of VEGFA mRNA in shYY1/
2 cells, IP with anti-YY1 antibodies which was restored in
sh.scramble cells (Suppl. Fig. 4A and B). Additionally, the interaction
was not detected without crosslinking, in RT-negative samples and
when non-speciﬁc IgG antibodies were used (Fig. 4B and Suppl.
Fig. 4A). During hypoxia, YY1 became ubiquitinated, TTP occupancy
was very low (Fig. 4C and Suppl. Fig. 4A, B) and HIF-1α antibody enriched
VEGFA mRNA by 160 fold in hypoxia compared to control (Fig. 4C and
Suppl. Fig. 4B). Interestingly, silencing of YY1/2 reduced the occupancy of
VEGFAmRNA by both TTP and HIF1α proteins in both normoxic and hyp-
oxic conditions (Fig. 4B, C and Suppl. Fig. 4A, B). This ﬁnding supports the
hypothesis that YY1 is necessary to stabilize HIF-1α and TTP on VEGFA
mRNA. Therefore, we tested whether there was a direct interaction
among these factors, and western blots, following immunoprecipitation,
conﬁrmed that YY1 bound both HIF-1α and TTP proteins (Fig. 4D). The in-
teractionwasnotdetectedwhen IgGantibodieswereused (Fig. 4D). Silenc-
ing of TTP determined an increase of VEGFA165/121mRNAs stability and a
decrease of protein suggesting that TTP regulated the translationalmachin-
ery of VEGFA (Suppl. Fig. 5).
2.5. YY1 recruits RNAi machinery component on VEGFA mRNA
In attempt to determine the mechanism of the YY1-dependent
VEGFA mRNA decay, we dosed mature and primiRNA 16 as well as
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Fig. 1. VEGFA mRNA isoform quantiﬁcation in osteosarcoma cells. A) Relative percentage of VEGFA 121, 165, and 189 mRNA isoform expression in normal and osteosarcoma cell lines.
B) Absolute quantiﬁcation of VEGFA 165 and 121 mRNAs, by q-PCR in Ost cells, U2os and Saos cells stable transfected with pBlock-it vector or with pBlock-it shYY1/2 construct. Data
are expressed as fg of mRNA. Serial dilutions of plasmid containing cDNA for 18S rRNA were used to set up a calibration curve.**p b 0.05 vs. U2os pBlock-it cells; *p b 0.05 vs. Saos
pBlock-it cells. Data shown are representative of three independent experiments performed in triplicate reported asmean value± SD. C) VEGFA ELISA of conditionedmedia fromdifferent
cell lines. Data are reported as pg/ml after 48 h of incubation inminimummedia and plating 1 × 104 cells/ml. D) Representativewestern blot of VEGFA from conditionedmedia of Ost cells,
U2os and Saos cells stable transfectedwith control vector, U2os and Saos YY1/2 silenced. The lower rows representwestern blots of total protein extracts fromdifferent cell lines incubated
with YY1 antibody; γ-tubulinwas used as loading control. E) Real time PCR of VEGFA 165/121 isoforms in Saos pBlock-it cells at different time of CoCl2 exposition. The relative expression
of VEGFA transcriptswas calculated by the 2−ΔΔCTmethod as fold-change of VEGFA 121 and 165 isoforms levelmeasured in Saos pBlock-it cells at time=0,wasﬁxed equal to 1 (reference
sample). Data are representative of three independent experiments performed in triplicate which were reported as man value ± SD. F) Representative western blot of whole lysate and
cultured media from different cell lines with HIF-1alpha, YY1, TTP and VEGFA antibodies after 6 h of CoCl2 incubation. γ-tubulin was used as loading control G) Densitometric analysis of
western blot showed in panel F. **p b 0.05 vs. Saos pBlock-it normoxia; *p b 0.001 vs. pBlock-it shYY1/2 Saos normoxia. All data shown are representative of three independent
experiments.
977T. Infante et al. / Biochimica et Biophysica Acta 1853 (2015) 975–986mature and primiRNA 200b/c. We employed the widely used online
software TargetScan 5.2 to search for the putative binding sites of
miRNAs in the 3′UTR of VEGFA mRNA. We selected these miRNAs be-
cause they target VEGFA 3′UTR close to YY1 binding sites [30,36,37].
Real time PCR data indicated that silencing of YY1/2 determined a
very low accumulation of primiRNA 16 and a ﬁve-fold accumulation of
primiRNA 200c, in comparison to control cells (Saos pBlock-it andSaos sh.scramble). Additionally, hypoxia induced accumulation of
primiRNAs 200b/c in all cell lines compared to normoxia condition
(Fig. 5A–C). Similarly, hypoxia induced reduction of their mature
forms. To understand whether YY1 is involved in driving the compo-
nents of the RNAi machinery by direct binding, we performed RNA
ChIP assays preceded by incubation with or without DNAase. RNA im-
munoprecipitation with YY1 antibody and real time PCR revealed that
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amount signiﬁcantly (p b 0.01) compared to input RNA (no IP) and
not detected when IgG antibodies were used (Fig. 6A–F). The bindingYY1/primiRNA 16 was DNA-dependent while primiRNA200c was inde-
pendent. RNAChIPwith YY1 antibody, followed by a further IP stepwith
either Dicer or Ago1 antibodies showed that YY1 enriched again
A5’ 3’
YY1 binding
sites
1                           2                        3             4     5               6             7                   8 UTR
region 1 region 2
Genomic VEGFA DNA
chr6:43752323+43752800 chr6:43753242+43753823
0
2
4
6
8
10
Ch
IP
Fo
ld
en
ric
hm
en
t
In
pu
t=
1
Normoxia
B
*
C
0
5
10
15
20
25
Ch
IP
Fo
ld
en
ric
hm
en
t
in
pu
t=
1
Hypoxia
*
region 1
**
region 2
region 1
region 2
**
Region 1
5’CCTCAGGGTTTCGGGAACCAGATCTCTCA
CCAGGAAAGACTGATACAGAACGATCGATA
CAGAAACCACGCTGCCGCCACCACACCATC
ACCATCGACAGAACAGTCCTTAATCCAGAAA
CCTGAAATGAAGGAAGAGGAGACTCTGCGC
AGAGCACTTTGGGTCCGGAGGGCGAGACTC
CGGCGGAAGCATTCCCGGGCGGGTGACCC
AGCACGGTCCCTCTTGGAATTGGATTCGCC
ATTTTATTTTTCTTGCTGCTAAATCACCGAGC
CCGG3’
Region 2
5’AGACACATTGTTGGAAGAAGCAGCCCA
TGACAGCTCCCCTTCCTGGGACTCGCCC
TCATCCTCTTCCTGCTCCCCTTCCTGGGG
TGCAGCCTAAAAGGACCTATGTCCTCAC
ACCATTGAAACCACTAGTTCTGTCCCCCC
AGGAGACCTGGTTGTGTGTGTGTGAGTG
GTTGACCTTCCTCCATCCCCTGGTCCTTC
CCTTCCCTTCCCGAGGCACAGAGAGACA
GGGCAGGATCCACGTGCCCATTGTGGAG
G3’ 
YY1 binding sites
Fig. 3. Chromatine status of VEGFA gene during hypoxia. A) Schematic of the VEGFA gene showing the intron-exon organization and the YY1 binding sites predicted byMatInspector pro-
gram that aremainly located in the 3′UTR region. The positions of YY1 binding sites aremarked in region 1 and region 2 sequences. B) Bar graph of q-PCR carried out on ChIP pulled-down
DNA by using different antibodies as indicated in the ﬁgure following ampliﬁcation of region 1 and region 2 of VEGFA 3′UTR. Data are reported as fold enrichment over input sample (non
immunoprecipitatedDNA and ampliﬁedwith speciﬁc primers). Refer to Saos pBlock-it cells cultured in normoxia * and ** denote p b 0.05 comparedwith 3′UTR region 2. C) Bar graph of q-
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F) again not detected when IgG antibodies were used (Suppl. Fig. 6A
and B). This data suggests a possible interaction between YY1 and
Dicer complex. Protein immunoprecipitation conﬁrmed that YY1
bound both Dicer and Ago1 proteins within the nucleus, thus forming
a ternary complex (Fig. 6G). During hypoxia, when tumor cells require
high level of VEGFA, protein immunoprecipitations revealed that YY1
and Dicer were both ubiquitinated (Fig. 7A). This phenomenon was
less evident in shYY1/2 cells (Fig. 7A). Western blot analysis conﬁrmed
an increasing ubiquitination of YY1 protein subjected to an increasing
time of hypoxia (Fig. 7B) without a signiﬁcant variation of the total
amount of protein. Moreover, time-course analysis of YY1 and Dicer
mRNAs under hypoxic conditions showed a reduction of Dicer mRNA
and a modest increase of YY1 expression, the latter being evident only
after 24 h of hypoxia (Fig. 7C) suggesting that both transcriptional
and post-transcriptional regulation of YY1 during hypoxia inﬂu-
enced its total amount. The possible mechanism of associationbetween epigenetic modiﬁcation of YY1 and post-transcription regula-
tion and VEGFA expression is illustrated in Fig. 8.
3. Discussion
Our data indicate that YY1 as a bivalent bridge between VEGFADNA,
mRNA and primiRNAs 16, 200b/c targeting VEGFA 3′UTR via Dicer
protein [1,36,37]. Under our experimental conditions, we observed
that YY1–RNA interaction is necessary to load and stabilize HIF-1α
and TTP proteins [32,38–41]. Silencing of YY1 prejudices the binding
of such proteins to VEGFA mRNA and the maturation of primiRNA
200b/c.
It was already reported that YY1 can also bind RNA as for eutheri-
an Xist/XIST element during X chromosome inactivation [35]. How-
ever, our ﬁndings insert YY1 in a more general mechanism of post-
transcriptional regulation through the recruitment of primiRNAs
machinery on chromatin complex favoring or inhibiting their corrected
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mean values± S.D. of three different experiments, performed in triplicate. D)Representative immunoprecipitation of total protein extracts fromU2os cellswith YY1 antibody andwestern
blot with TTP antibody and vice versa. Immunoprecipitation with YY1 antibody and detection with HIF-1α antibody. IgG immunoprecipitations were performed as control. All data are
representative of three different experiments.
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well recognized that YY1 protein may act as positive or negative tran-
scription regulator, [15] here we describe its double face in normoxia
and hypoxia conditions based on its epigenetic modiﬁcation.
Hypoxia is thought to induce alteration in tumor gene expression
pathways such as VEGFA by controlling its mRNA stability [38–40,42],altering miRNA activity [43] and inducing chromatin modiﬁcations [1].
In this context our data are consistent with hypothesis that YY1 is neces-
sary toHIF1α stabilization [40] andhistone ubiquitination during hypox-
ia [44,45]. Although, histone ubiquitination is one of the mechanisms by
which PRC1 complexes use to silence target genes and, in turn regulate a
broad array of biological processes [5,45,46], this is the ﬁrst time that this
Table 1
R. Catena, et al Int. J. Cancer. 120 (2007) 2096-2109.
NCBI accession number Gene expression Forward primer Reverse primer Genomic position
NM_022551 RPS18 CGATGGGCGGCGGAAAATA CTGCTTTCCTCAACACCACA chr6:4472697 + 4475855
NM_002046 GAPDH ACATGTTCCAATATGATTCCA TGGACTCCACGACGTACTCAG chr12:6645854 + 6646144
Total Pro VEGFA ACTTTCTGCTGTCTTGGGTG GGCACACAGGATGGCTTGA *Catena R. et al., 2007
Total anti VEGFA CTTCCTACAGCACAACAAATG TTCCTGGTGAGAGATCTGCA
Pro VEGFA 165 GACAAGAAAATCCCTGTGGG TACAAACAAATGCTTTCTTCC 5/7 exon junction
Anti VEGFA 165 GACAAGAAAATCCCTGTGGG TTCCTGGTGAGAGATCTGCA 5/7b exon junction
NM_003376 Pro VEGFA 121 ATAGAGCAAGACAAGAAAAATG ATCGTTCTGTATCAGTCTTTCTT 5/8 exon junction
Anti VEGFA 121 GAAAAATCTCTCACCAGGAAA CTGGATTAAGGACTGTTCTG 5/8b exon junction
Pro VEGFA 189 GAGGAAAGGGAAAGGGGCA TACAAACAAATGCTTTCTTCC 6/7 exon junction
Anti-VEGFA 189 GAGGAAAGGGAAAGGGGCA TTCCTGGTGAGAGATCTGCA 6/7b exon junction
NM_003403 YY1 ATGGCCTCGGGCGACACCCT GTCGTCGTCCTCCTCCTCCT chr14:100705582 + 100705731
NM_030621 Dicer TCCACGAGTCACAATCAACACGG GGGTTCTGCATTTAGGAGCTAGATGAG chr14:95579503 + 95582045
NCBI accession number primiRNA expression Forward primer Reverse primer Genomic position
RF00026 (RFAM database) U6 CTCGCTTCGGCAGCACATAT AACGCTTCACGAATTTGCGT chr7:150064036 + 150064063
MI0000070 (miRBase database) hsamir-16 TAGGCGCGAATGTGTGTTTA CAACCTTACTTCAGCAGCACAG chr13:50623111 + 50623369
MI0000342 (miRBase database) hsamir-200b TACTGAGCTTCCCAGCGAGT CGTCATCATTACCAGGCAGT chr1:1102431 + 1102563
MI0000650 (miRBase database) hsamir-200C CAGGGATCTGCAGCTTTTCC ACCTGAGGCGATGGATGTT chr12:7072787 + 7072967
NCBI accession number DNA chip Forward primer Reverse primer Genomic position
NM_002046 GAPDH promoter GCTGGATGGAATGAAAGGCACAC ATCTCCTGGCTCCTGGCATCTC chr12:6642746 + 6643087
VEGF 3′UTR region 1 CCTCAGGGTT TCGGGAACCA TCCTCTTCCTTCATTTCAGG chr6:43752323 + 43752800
VEGF 3′UTR region 2 GACACATTGT TGGAAGAAGC TTCTTTGGTGTGAGGACATA chr6:43753242 + 43753823
NCBI accession number Cloning (reported only forward primers)
NM_003403/NM_206923 Mir-shYY1/2 TGCTGTATGAGGGCAAGCTATTGTTCGTTTTGGTTTTGGCCACTGACTGACTGACGAACAATAGCTTGCCCTCATAC
Mir1-shTTP TGCTGTCTCTGAGAAGGTCCGACATAGTTTTGGCCACTGACTGACTATG
NM_003407 Mir2-shTTP TCGGCTTCTCAGAGACAGGACACAAGGCCTGTTACTAGCACTCACATGG
Mir3-shTTP AACAAATGGCCCTGGAGGCTTGCTGAAGGCTGTATGCTGGGGTGGGGTC
Mir4-shTTP TCTTCGAGCCAGTTTTGGCCACTGACTGACTGGCTCGAAGAGACCCCACCC
⁎ Catena R et al. Increased expression of VEGF121/VEGF165-189 ratio results in a signiﬁcant enhancement of human prostate tumor angiogenesis. Int J Cancer. 2007;120 (10):2096-109.
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cause YY1 shifts position during hypoxia, we believe that it determines
a site speciﬁc ubiquitination of histone complexes [45] as well as Dicer
[47]. Ubiquitination of both YY1 and Dicer favors nuclear accumulation
of immature primiRNA 200b/c [1,29,47]. The effect of chronic hypoxia
on Dicer protein and down regulation of mature microRNAs is not
a very new ﬁnding in endothelial cells [47,48], however, our observa-
tion indicates for the ﬁrst time that polycomb YY1 mediates histone
ubiquitination at the 3′UTR of VEGFA, in site speciﬁc manner to main-
tain the induction of hypoxia-responsive genes through epigenetic
and post-transcriptional (i.e., microRNA regulation)mechanisms inma-
lignancy. Relevantly, this represents a novel, previously uncharacterized
facet of microRNAsmachinery regulation by polycomb epigenetic mod-
iﬁcation (as shown in cartoon of Fig. 8). These ﬁndings could be relevant
to microRNA function in pathobiology of cellular transformation.
Finally, although it is well described that YY1 protein may act as
positive or negative transcription regulator here we described its dou-
ble face in normoxia and hypoxia conditions due to its epigenetic
modiﬁcation.4. Conclusions
Our ﬁndings underline the role of YY1 in the posttranscriptional
regulation of VEGFA with different roles in normoxia versus hypoxia
on the base of its epigenetic modiﬁcation.
The binding of YY1 to 3′UTR of VEGFA mRNA plays a key function
role in the miRNAmachinery. Indeed YY1 silencing or its ubiquitination
during hypoxia determines accumulation of immature primiRNA 200b/
c. The evidence is of particular interest in the study of the mechanisms
that links epigenetic modiﬁcations to miRNA machinery.
However, still, further investigations are needed to better deﬁne the
network between epigenetic mechanism and miRNA machinery and to
determine YY1 up and downstream partners.5. Material and methods
5.1. Cell lines
HumanSaos, U2os, (fromATCC) and silenced clonedwere cultured in
Dulbecco's modiﬁed Eagle's medium (DMEM) (Lonza) with 10% fetal
bovine serum (FBS), 2 mM of L-glutamine, and 10 U/mL of penicillin/
streptomycin (Lonza). Osteoblast cells were grown in α-MEM (Lonza)
containing 10% (FBS), 2 mM of L-glutamine, and 10 U/mL of penicillin/
streptomycin (Lonza). For hypoxic treatment cells were incubated in
the presence of 150 μM CoCl2 for different times. All cell lines were
grown in a humidiﬁed incubator, at 37 °C and 5% CO2.
5.2. RNA extraction and reverse transcription
RNA was extracted using TRIzol reagent (Invitrogen) according to
manufacturer's recommendations. For cDNA synthesis, reverse tran-
scriptionwas performed using Transcriptor First Strand cDNA Synthesis
Kit (Roche) with 1 μg of total RNA, 2 μl of random hexamer and 10 μl of
PCR grade water. The template-primer mixture reaction tubes were
then heated at 65 °C for 10 min in a thermal block cycler. The tubes
were then immediately cooled on ice and added the cDNA synthesis
mix: Transcriptor Reverse Transcriptase Reaction buffer (4 μl), Protector
RNase Inhibitor (0.5 μl), deoxynucleotide mix (2 μl) and Reverse Tran-
scriptase (0.5 μl), for a ﬁnal volume of 20 μl. The reaction was subjected
to 60 min extension step at 50°°C and 5 min termination step at 85 °C.
5.3. MicroRNA isolation and analysis
miRNAs were isolated from cells using PureLink® miRNA Isolation
Kit (Invitrogen) and reverse transcribed with NCode™ First Strand
cDNA Synthesis Kit (Invitrogen) according to manufacturer's protocol.
The primiRNA-speciﬁc ampliﬁcation of miR-16 (MIMAT0000069),
miR-200b (MIMAT0004571), and miR-200c (MIMAT0004657), see
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Fig. 5. YY1 silencing and primiRNA 16, and 200b/c accumulation. A) Bar graph of qRT-PCR
reported as 2−ΔΔCT for primiRNA and mature miRNA 16 in pBlock-it, pBlock-it shYY1/2
and pBlock-it sh.scramble Saos cells in normoxia and hypoxia (6 h of CoCl2 treatment).
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hsa-miR-200b-3p LNA™ PCR primer set, UniRT MIMAT0000318, hsa-
miR-200c-3p LNA™ PCR primer set, UniRT MIMAT0000617 and hsa-
miR-16-2-3p LNA™ PCR primer set, UniRT MIMAT0004518, (Exiqon).
5.4. Real-time PCR
Real time PCR was performed using a set of speciﬁc primers for all
VEGFA exons designed to amplify unique splicing variants or all splicing
variants (total VEGFA) (see Table 1). Reactions (25 μL) contained 1 μL
cDNA, 0.2 μM primers, and 12.5 μL SYBRGreen Master Mix (Applied
Biosystem). The reaction was subjected to a hot start for 10 min at 95 °C
and 30 cycles of 95 °C for 10 s, 47° C for 15 s, 60 °C 30 s. Real time PCR
was performed using a Light-Cycler rapid thermal cycler system (Bio-
Rad) according to the manufacturer's instructions. Melt curve analysis
was performed to verify the speciﬁcity of the PCR. Each sample was
run in triplicate, and Ct was determined for the target gene. Results
were normalized to 18S rRNA levels. mRNA and 18S rRNA relative
fold changes were calculated using either absolute quantiﬁcation with
plasmid standard curves or the comparative 2−ΔΔCT method. Quantita-
tive RT-PCR/First strand cDNA synthesis and TaqMan humanmicroRNA
assays and a TaqMan microRNA reverse transcription kit (Applied
Biosystems) were used for microRNA measurements according to the
manufacturer's recommendations. Results were normalized to U6
snRNA levels. PrimiRNA and U6snRNA relative fold changes to non-
immunoprecipitated material were calculated using the comparative
2−ΔΔCT method.
5.5. VEGFA dosage by ELISA
Dosage of VEGFA in culture media was performed using Human
VEGFA ELISA Quantikine kit (R&D Systems). 2 × 106 of cells were seeded
in Opti-MEM medium (Gibco). After 48 h the assay was performed on
conditioned media following the manufacturer's recommendations. The
absorbance was measured at 450 nmwith a microplate reader (Inﬁnite
M200,TECAN).
5.6. Inhibition of transcription
Assay was performed in 6-well plates and 1 × 105 cells were seeded
in eachwell. Cellswere incubatedwith 10 μg/ml actinomycin-D (Sigma-
Aldrich) and total RNA was extracted at different times (0, 30 min, 1 h,
4 h, 6 h).
5.7. mRNA half-life determination
Conﬂuent cells were subjected to 6 h of normoxia or hypoxia after
which actinomycin-D (Sigma Italy) was added to a ﬁnal concentration
of 10 μM, then total cellular RNA was extracted at (0, 2, 4, 6, and 24 h).
PD98059 and SB239063 (Sigma, Italy) were added to actinomycin D-
treated cells to a ﬁnal concentration 10 μM. For hypoxia condition CoCl2
(Sigma, Italy) was added to cell culture at ﬁnal concentration of 150 μM.
5.8. Chromatin immunoprecipitation (ChIP)
ChIP experiments were performed as described previously [16] by
using the following antibodies: Trimethyl-histone H3Lys27 (07-449
Merk Millipore), monoubiquityl-Histone H2A (Lys119), (clone E6C5
Merk Millipore), pan ubiquitine (ab7780 Abcam), and YY1 (C20 Santa
Cruz Biotechnology).
5.9. RNA-chromatin immunoprecipitation (RNA-ChIP)
1 × 107cells were ﬁxed with 1% formaldehyde for 10 min at room
temperature. The cells were washed extensively with PBS, and the
chromatin was sheared by sonication (Bioruptor, Diagenode). The
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used as experimental control.
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following antibodies: YY1 (C20, Santa Cruz Biotechnology), HIF-1α
(AF1935, R&D), tristetraprolin (TTP) (A-8, Santa Cruz Biotechnology),
pan ubiquitine (ab7780 Abcam), trimethyl-histone H3Lys27 (07-449
Millipore), Dicer (13D6) (ab14601, Abcam) and Argonaute 1 (Ago1)
(NB100-2817, Novus Biologicals) at 4 °C overnight. Normal mouse IgG
was used as negative controls. Immunocomplexes were pulled downthrough A/G plus resin (Santa Cruz Biotechnology) incubation and
RNA, obtained from the decross-linking reaction, was retrotranscribed
and ampliﬁed by qPCR. Real time PCRs were performed with primer
mapping on junction exons 5/7 (called 165 Forward and 165 Reverse
primers as indicated in Table 1) and expressed as delta CT of the house-
keeping gene and fold change to non-immunoprecipitated samples.
DNAasi (Sigma-Aldrich) was used at ﬁnal concentration of 10 μM.
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Fig. 8.Model for posttranscriptional regulation of VEGFA by YY1-miRNAs complexes. In normoxia YY1 is recruited at its binding site on VEGFA 3′UTR: It forms a complex with VEGFA
mRNA and miRNA machinery (steady state). In hypoxia YY1 recruits histone H2A ubiquitination on VEGFA 3′UTR and forms a bridge between histone and Dicer. Chromatin in this
conformation correlates with primiRNA and VEGFA mRNA accumulation.
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For the stable silencing of YY1/2 in Saos and U2os cells was used
pBLOCK-iT U6 RNAi GFP entry Vector kit (invitrogen) using the follow-
ing oligonucleotide.
(TGCTGTATGAGGGCAAGCTATTGTTCGTTTTGGTTTTGGCCACTGACT
GACTGACGAACAATAGCTTGCCCTCATAC or Scramble oligos. For silenc-
ing of TTP family of protein the oligonucleotides sequences used are
showed in Table 1. Then, 1 μg of recombinant constructswas transfected
into 24-multiwell (20.000 cells/well) using FuGENE® HD Transfection
Reagent (Roche) and stable clones were selected by using Blasticidin
(10 μg/ml). The recombinant constructs expressed EGFP as fusion
protein.
5.11. Western blot
Total cellular proteins were size-fractionated on NuPAGE Novex
4–12% Bis–Tris or 3–8% Tris acetate gels (Invitrogen) using Mini-Cell
(Biorad) and transferred onto 0.45-μm nitrocellulose membranes
using the XCell II Blot Module (Biorad) according to the manufacturer's
recommendations. The following primary antibodies were used: Dicer
(13D6) (ab14601, Abcam), Argonaute 1 (Ago1) (NB100-2817, Novus
Biologicals), HIF-1α (AF1935, R&D Systems), VEGFA (AF-293-NA R&D)
and VEGFA (F-5, Santa Cruz Biotechnology) and YY1 (C20, Santa Cruz
Biotechnology). The following secondary antibodies were used: horse-
radish peroxidase (HRP)-conjugated rabbit anti-mouse IgG (heavy and
light) (ab6728, Abcam), HRP-conjugated goat antirabbit IgG (sc-2004,
Santa Cruz Biotechnology), and HRP-conjugated donkey anti-goat IgG
(sc-2020, Santa Cruz Biotechnology). Signal quantiﬁcation was per-
formed using NIH ImageJ and normalized to loading control (γ tubulin
Sigma).
5.12. Statistical analysis
Data are presented as mean ± SD or SEM, derived from at least 3
independent experiments. Statistical signiﬁcance between means was
assessed by Student t test. p b 0.05 was considered signiﬁcant.
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